Stevanato Group 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Stevanato Group reported third-quarter 2026 revenue of $326.1 million, up 8% both reported and organically compared with the third quarter of 2025.
- BDS revenue was $294 million, up 10% reported and 11% organically; engineering revenue was $32 million, down 12%.
- High-value solutions revenue increased 1% to $149.4 million and represented 46% of total revenue; within BDS, high-value solutions represented approximately 51% of segment revenue.
- Adjusted EBITDA grew 14% to $88.8 million, and adjusted EBITDA margin increased 150 basis points to 27.2%. Net profit grew 16% to $41.8 million; adjusted net profit increased 14% to $44 million, and adjusted diluted EPS was 16 cents.
- Gross profit margin decreased 10 basis points to 29.1%, while operating profit margin increased 110 basis points to 18.5% and adjusted operating profit margin increased 90 basis points to 19.4%.
- Revenue from non-GLP biologics increased over 30% in the quarter and was up 13% year to date; GLP-1 revenue was approximately 17 to 18% of total company revenue.
- The company ended the quarter with cash and cash equivalents of $114.9 million and net debt of $353.7 million. Capital expenditures totaled $44.8 million, and free cash flow was $21.7 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon. This is the Chorus Call conference operator. Welcome and thank you for joining the Stevanato Group Third Quarter Financial Results Conference Call. As a reminder, all participants are in listen-only mode, and after the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Ms. Lisa Miles, Chief Communication and IR Officer.
Please go ahead, madam. Good morning, and thank you for joining us.
With me today is Franco Stevanato, Chairman and Chief Executive Officer, and Marco Dal Lago, Chief Financial Officer. We have posted a presentation to accompany today's results on the Investor Relations page of our website, which can be located under the Financial Results tab. I want to remind everyone that some statements being made today are forward-looking and based on current expectations. Actual results may differ materially due to risks outlined in Item 3.D, Risk Factors, of our most recent annual report on Form 20-F filed with the SEC. Please review the safe harbor statement included at the beginning of today's presentation and in our press release. The company undertakes no obligation to revise or update these forward-looking statements, except as required by law. Today's presentation may include non-GAAP financial information.
Management uses these measures internally to assess performance and believes they may be helpful for investors in evaluating the quality of our financial results, identifying trends in our performance, and providing meaningful period-to-period comparisons. Please note that for today's call, we are introducing a new non-GAAP measure, organic revenue, for the purpose of offering a proper year-on-year comparison. Organic revenue is defined as reported revenue, excluding the effects of divestments and/or acquisitions and the impacts of foreign currency translation. For a reconciliation of these non-GAAP measures, please refer to the company's most recent earnings press release. With that, I will now hand the call over to Franco Stevanato.
Thank you for joining us. Today, we review our third quarter performance, share an update on market trends, and discuss the current market environment. Our third quarter financial results were in line with our expectations. Reported and organic revenue grew 8%. High-value solutions represented 46% of the total revenue, and adjusted EBITDA increased 150 basis points to 27.2% compared to the third quarter of 2025. Revenue growth was driven by an 11% increase on an organic basis in the biopharmaceutical and diagnostic solutions segment, which offset a 12% decline in the engineering segment. Revenue related to GLP-1s decreased in the third quarter and was approximately 17%-18% of the total company revenue. Revenue from non-GLP biologics increased over 30% in the quarter, offsetting the decline from GLP-1s. On a year-to-date basis, revenue from non-GLP biologics was up 13%, demonstrating once again the diversity of the broader demand landscape.
In the second and third quarters of fiscal 2026, we recorded variable compensation in the BDS segment tied to lower volumes mostly related to GLP-1 therapies. Turning to next year, we are working through the binding forecast process with our customers. Forecasts are consistent with the trends we experienced thus far in 2026, with increasing demand across our high-value portfolio from most of our customers. However, within our GLP portfolio, we now expect lower volumes than previously anticipated for 2027. This was not entirely unexpected, and we started taking action several months ago to offset this impact. For example, the flexibility of our global operations allowed us to move some capacity to different regions to accommodate higher demand from other customers. More importantly, we currently expect consistent strong demand in non-GLP biologics in 2027.
We are still in the process of finalizing customer production forecasts for next year, and we are confident that we have already backfilled the majority of this revenue. We now expect this will result in a temporary moderation of growth in fiscal 2027. Looking ahead, GLPs remain a phenomenal drug class, and we expect to continue to benefit in the long term. Currently, our GLP revenue is predominantly tied to commercial products from the main originators. However, we are actively working with over 30 global customers for multiple programs in various stages of clinical development. These new customer programs are expected to play an important role in future growth, and they utilize high-value products, including our EZ-fill platform and proprietary delivery devices. Today, the global patient penetration is well below 10%, and the opportunity remains significant and largely untapped.
The overall demand environment for injectable biologics remains structurally strong, underpinned by long-term durable tailwinds. Scientific innovation is driving global pipelines with novel therapies expanding patient reach. Moreover, technology advancements are providing breakthrough solutions that enhance patient convenience and adherence. New formulation and delivery technologies allow for self-injection of highly viscous and higher volume drugs. This is critical, as treatments delivered intravenously in a hospital setting transition to a subcutaneous presentation that can be administered by patients at home. This offers clear advantages for patients and in reducing healthcare costs. Lastly, we continue to see growing demand for high-performing containment and off-the-shelf delivery systems to support the larger wave of biosimilars approaching the market in the coming years.
Beyond GLPs, our customers are building a wide biosimilar pipeline, including assets in immunology, oncology, endocrinology, and other therapeutic areas that will expand patient access globally and represent a very attractive opportunity for us in the medium and long term. In response to these market trends, we are squarely focused on meeting customer needs with new technology, innovation, and additional production capacity. Our Alba syringe platform is a great example of this innovation. It is our highest-performing syringe platform and has unique features that have led to growing market demand. In recent weeks, we qualified our first high-volume Alba syringe line in our Piombino Dese plant. Customer demand also remains solid across other EZ-fill platforms. We continue to run production of our EZ-fill cartridges at full utilization, and we are progressively increasing production for EZ-fill vials as demand continues to expand to a larger set of customers.
Moving to delivery devices, the opportunity pipeline for our proprietary platform continues to grow. Our Alina, Aidaptus, and Deora platforms are in various stages of evaluation for a diverse range of biologic application, mainly biosimilars, including GLP-1s and metabolic disease, endocrinology, immunology, cardiovascular diseases, and other therapeutic areas. Our customers' needs are clear, pointed at solutions that enhance patient usability and adherence, de-risk supply chain, provide a better answer to new drug product requirements of modern formulations, and lastly, increase the sustainability and efficiency profile of combination products. We believe we have the right set of products, expertise, and competencies to support our customers with a broad and unique value proposition. Let's turn to the engineering segment. The operations have stabilized, and efforts under our optimization plan have created operational improvements, but financial results in the third quarter were below our expectations.
We made good progress with new order intake last quarter, but we ended the third quarter below our target levels of signed new orders. This was due in part to a number of orders that have been delayed from a large customer, which put pressure on the segment in 2026. Our guidance now reflects a slight adjustment to our full year 2026 revenue expectation for the engineering segment. This is expected to be fully offset by better performance in the BDS segment and has no impact on consolidated guidance. Marco will provide more details. Let's review the progress of our growth initiative in U.S. and in Italy. During the third quarter, we continued to scale this investment with discipline, further enhancing operational maturity and increasing capacity to support customer demand. In Latina, commercial operations for EZ-fill syringes are running smoothly, and we continue working on customer audit and validation activities.
Looking ahead, the team is busy preparing the facility for the next phase of expansion, which is dedicated to EZ-fill ready-to-use cartridges. Demand for high-value cartridges remains strong, with the market expanding beyond the traditional cartridge players. Our new LT400 cartridge lines are the first of their kind, driving significant innovation and production capacity. This includes a new aseptic crimping process to ensure sterility at the cartridge interface and maintain closure integrity in aseptic conditions. This is one of the most distinctive features and a key enabler for protecting the final product throughout the sterile packaging flow. With new production of EZ-fill cartridges in Latina, customers now have greater supply chain security, while at the same time, it gives us greater operational flexibility.
Moving to Fishers, I'm pleased to report that the site broke even at the gross profit margin level in the third quarter, achieving another important milestone as we scale this multi-year investment. More recently, we shipped the first commercial EZ-fill vial order, while customer audit and validation continue alongside ongoing line installations. During the third quarter, we completed the build-out of device manufacturing clean room. We remain on track to launch commercial volumes in the next couple of months. We are in the early phase of commercialization for our device programs. Over the next 18 months, our facilities in Fishers and in Germany will be focused on a significant commercial scale-up for contract manufacturing and our proprietary Alina pen injector. In summary, the overall demand environment for injectable biologics remains solid, driven by strong secular tailwinds such as aging population, scientific innovation, and the rising trend of self-administration of medicine.
We have positioned the business in the most attractive area of the market that require high-performance products. Our broad product portfolio addresses these needs, from our groundbreaking Alba syringe platform to our large-volume cartridges and our integrated drug delivery systems, such as our Alina pen. Robust market demand in biologics and biosimilars give us the confidence that we can backfill the lower GLP revenue and still grow low single digit in 2027. I'll turn the call over to Marco for a review of our third quarter financials.
Thanks, Franco. Before I begin, I'd like to clarify that all comparisons refer to the third quarter of 2025. Let's start on page 10. In the third quarter of 2026, revenue grew 8% to EUR 326.1 million, both on a reported basis and organically. This was driven by 11% organic growth in the BDS segment, which offset the 12% revenue decline in the engineering segment. Revenue from high-value solutions increased 1% to EUR 149.4 million, both on a reported basis and organically, and accounted for 46% of total revenue. In the third quarter of 2026, gross profit margin decreased 10 basis points to 29.1% and was unfavorably impacted by increased utility costs, the expected higher depreciation, and lower gross profit in the engineering segment. This was partially offset by the combined improvements in Latina and Fishers and a better mix compared to last year.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
